Month: Unilateral Peripheral Lung Opacity » Medical Image of the Month: Bleomycin-Induced Pulmonary Fibrosis in a Patient with Lymphoma

M. Dufwenberg
{"title":"Month: Unilateral Peripheral Lung Opacity » Medical Image of the Month: Bleomycin-Induced Pulmonary Fibrosis in a Patient with Lymphoma","authors":"M. Dufwenberg","doi":"10.13175/swjpcc024-21","DOIUrl":null,"url":null,"abstract":"Interstitial pulmonary fibrosis is the most feared complication of bleomycin therapy and occurs in up to ten percent of patients that receive the drug. The risk of bleomycin-induced pulmonary fibrosis is related to the age of the patient, the dose of medication given, the patient’s kidney function, and whether the patient smokes cigarettes. Current screening guidelines for bleomycin-induced lung injury are limited, but most clinicians screen high risk and symptomatic patients with pulmonary function testing. This case report is of a patient with lymphoma who received bleomycin as a part of his chemotherapy regimen, and later developed pulmonary fibrosis complicated by bouts of eosinophilic multifocal pneumonia. The case highlights the importance of close monitoring of patients taking bleomycin for signs and symptoms of pulmonary fibrosis and the need for major medical societies to issue concrete screening guidelines.","PeriodicalId":87365,"journal":{"name":"Southwest journal of pulmonary & critical care","volume":"42 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southwest journal of pulmonary & critical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13175/swjpcc024-21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Interstitial pulmonary fibrosis is the most feared complication of bleomycin therapy and occurs in up to ten percent of patients that receive the drug. The risk of bleomycin-induced pulmonary fibrosis is related to the age of the patient, the dose of medication given, the patient’s kidney function, and whether the patient smokes cigarettes. Current screening guidelines for bleomycin-induced lung injury are limited, but most clinicians screen high risk and symptomatic patients with pulmonary function testing. This case report is of a patient with lymphoma who received bleomycin as a part of his chemotherapy regimen, and later developed pulmonary fibrosis complicated by bouts of eosinophilic multifocal pneumonia. The case highlights the importance of close monitoring of patients taking bleomycin for signs and symptoms of pulmonary fibrosis and the need for major medical societies to issue concrete screening guidelines.
本月医学影像:博莱霉素诱导的淋巴瘤患者肺纤维化
间质性肺纤维化是博来霉素治疗最可怕的并发症,在接受该药治疗的患者中发生率高达10%。博莱霉素诱发肺纤维化的风险与患者的年龄、给药剂量、患者的肾功能以及患者是否吸烟有关。目前博莱霉素引起的肺损伤的筛查指南是有限的,但大多数临床医生通过肺功能测试筛查高风险和有症状的患者。本病例报告是一个淋巴瘤患者接受博来霉素作为其化疗方案的一部分,后来发展为肺纤维化并伴有嗜酸性多灶性肺炎。该病例强调了密切监测服用博来霉素的患者肺纤维化体征和症状的重要性,以及主要医学协会发布具体筛查指南的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
1 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信